Changing the Course of Sepsis Treatment with 20-minute IL-6 Results

In sepsis, every hour of delayed treatment increases mortality by 4-9% (Sepsis Alliance). Symphony™ IL-6 closes that window.

The American Medical Association estimates 1.7 million adults in the U.S. develop sepsis annually and at least 350,000 die. Sepsis costs U.S. healthcare $24 billion annually (each ICU day is more than $4,000 per patient).

Using AI predictive modeling in concert with IL-6, Bluejay hopes to further improve outcomes. The Negative Predictive Value (NPV) for IL-6 Assay using Symphony is 98%, compared to traditional products ranging from 78.6% to 92.9% (FDA Emergency Use Authorization company filings).

Symphony IL-6 can accurately diagnose sepsis using as little as three drops of blood in Bluejay’s revolutionary cartridge. Once the cartridge is placed in the Symphony machine, results will be delivered within 20 minutes, a less than a quarter of the time traditional lab results take.

Symphony can potentially reduce unnecessary ICU days, shorten hospital stays, and lower readmissions.